Intestinal pseudoobstruction and pneumatosis cystoides intestinalis are uncommon complications of progressive systemic sclerosis. Wereport a 26-year-old womanwith this disorder who responded poorly to conventional treatment. Subcutaneous administration of octreotide, a longacting somatostatin analogue, at a dose of50 J^g/day for 3 weeks, relieved symptoms such as nausea and bloating. There was also a markeddecrease of intestinal gas accumulation, as documentedon X-ray films. (Internal Medicine 32: 607-609, 1993) 
Introduction
Intestinal pseudoobstruction and pneumatosis cystoides intestinalis are uncommoncomplications of progressive systemic sclerosis that generally respond poorly to treatment. Yonemitsuet al (1) reviewed 28 reported cases ofpneumatosis cystoides intestinalis in patients with progressive systemic sclerosis. Further, several other cases have been reported (2-7). Here, we describe a case of progressive systemic sclerosis associated with intestinal pseudoobstruction and pneumatosis cystoides intestinalis.
This patient showed a response to octreotide, a long-acting somatostatin analogue (8) .
Case Report
A 26-year-old womanwas first noted to have Raynaud's phenomenon in 1988, and was diagnosed as having progressive systemic sclerosis in 1990 (confirmed by skin biopsy). She was admitted to our hospital in May 1991 with severe nausea, vomiting, diarrhea, bloating, and fever. Physical examination demonstrated moderate skin changes consistent with progressive systemic sclerosis. The abdomenwas flat, soft, and nontender. Bowel sounds were decreased and plain X-ray of the abdomen showed a few dilated loops of small intestine. She was diagnosed as having intestinal pseudoobstruction associated with progressive systemic sclerosis, and was treated with total parenteral nutrition and prednisolone (5 mg/day). Prokinetic agents such as cisapride, metoclopramide, domperidone, and prostaglandin F2oc were also given, but had little effect. The patient was unable to maintain an adequate oral intake due to the persistence of symptoms, and she required continuation of hospitalization. Eight months later, she was admitted with severe abdominal pain and bloating. On examination, the abdomen was distended, soft, and nontender. Laboratory investigations showed no prominent abnormalities other than hyponutrition (Table 1 ) . Plain X-ray films revealed pneumoperitoneum ( Fig. 1 ). Since intestinal perforation could not be excluded, the patient underwent exploratory laparotomy. The small intestine was found to be grossly distended ( Fig. 2 ) and gas-filled cysts about 2 mmin diameter were present below the serosa, although they were not detected by X-ray. No perforation of the bowel wall was detected by naked eye examination. Gastrointestinal radiogram and endoscopic examination were not done, but gas-filled cysts were so small that it is doubtful whether these examinations would reveal pneumatosis cystoides. The early postoperative course wasuneventful. Octreotide, a long-acting somatostatin analogue (8) , was started at a dose of 50 |ig/day by subcutaneous injection on the 19th postoperative day, and was continued for three weeks. Symptomssuch as nausea and bloating were improved by this treatment and the amount of gas retained in the small intestine Ll:
mtr' -was markedly decreased. Figure 3 shows an abdominal X-ray film obtained before octreotide therapy, and Fig. 4 shows a film taken after three weeks of treatment. During this time, domperidone was also administered (30 mg/day), as well as oxygen. Oxygen was given at a dose of 3 liters/min from the early postoperative period and was discontinued before the end of this trial. After 3 weeks of daily administration, octreotide was continued at a dose of 100 jug on alternate days, but intestinal gas increased with this regimen. Accordingly octreotide was given on a daily basis again and the patient's condition improved, although not to the same degree as during the initial trial. Later discontinuation was attempted and was failed because of aggravation of the patient's symptoms. 
Discussion
Severe intestinal hypomotility is an uncommon complication of progressive systemic sclerosis that causes pseudoobstruction, bacterial overgrowth, and the accumulation of intestinal gas (9) . It also occasionally progresses to pneumatosis cystoides intestinalis. Although the pathogenesis of pneumatosis cystoides intestinalis in progressive systemic sclerosis is uncertain, excessive gas produced by bacterial overgrowth, maybe forced through microscopic breaks in the mucosa by increased intraluminal pressure and accumulate in Octreotide Therapy for PSS Fig. 4 . Aplain abdominalX-ray filmtaken after 3 weeks of octreotide therapy reveals a marked decrease of intestinal gas.
the bowel wall (6). Our patient presented a considerable management problem. There are few treatments available for intestinal hypomotility or pneumatosis other than conservative approaches such as permanent parenteral nutrition (9) , dietary therapy (9-1 1), antibiotics to reduce bacterial overgrowth (9, 10, 12) , Dpenicillamine (13) , and oxygen (6) . A successful outcome is rare in such patients. Stafford-Brady et al (6) reported a patient with colonic pseudoobstruction whosesymptomsdramatically improved following subtotal colectomy, but this case appears to be exceptional. A few authors have described a good response to treatment with prokinetic agents like methoclopramide ( 14) and cisapride (15) , but our patient failed to obtain any benefit from such agents. Octreotide is a somatostatin analogue (8) that is used for treating endocrine tumors. The reason for the successful treatment with octreotide in this patient is not clear at present. It might be possible that octreotide directly reduced the production of intestinal gas. However, somatostatin stimulates intestinal motility in normal individuals (16) and octreotide is known to produce a similar effect in dogs (17) . Indeed, Soudah et al ( 1 8) confirmed that octreotide increases intestinal motility in patients with progressive systemic sclerosis. They used octreotide to treat progressive systemic sclerosis associated with pseudoobstruction and found that the administration of a dose of 50 jig daily for 3 weeks decreased nausea, bloating, and abdominal pain, and also reduced bacterial overgrowth as determined by breath hydrogen excretion. They presumed that the motor effects of octreotide reduced intestinal stasis, thereby allowing bacterial clearance.
The sametreatment produced a short-term improvementin our patient, but the response decreased subsequently. However octreotide is still being administered because the patient's symptomsworsened upon discontinuing the drug.
